RBD-Modified Bacterial Vesicles Elicited Potential Protective Immunity against SARS-CoV-2
Zhongqian Yang, Liangqun Hua, Mengli Yang, Shu-Qun Liu, Jianxin Shen, Weiran Li, Qiong Long, Hongmei Bai, Xu Yang, Zhaoling Ren, Xiao Zheng, Wenjia Sun, Chao Ye, Duo Li, Peng Zheng, Jinrong He, Yongjun Chen, Weiwei Huang, Xiaozhong Peng, Yanbing Ma
Abstract
The disease caused by SARS-CoV-2 infection threatens human health. In this study, we used high-pressure homogenization technology not only to efficiently drive the bacterial membrane to produce artificial vesicles but also to force the fusion protein ClyA-receptor binding domain (RBD) to pass through gaps in the bacterial membrane to increase the contact between ClyA-RBD and the membrane. Therefore, the load of ClyA-RBD on the membrane is substantially increased. Using this technology, we constructed a "ring-like" bacterial biomimetic vesicle (BBV) loaded with polymerized RBD (RBD-BBV). RBD-BBVs injected subcutaneously can accumulate in lymph nodes, promote antigen uptake and processing, and elicit SARS-CoV-2-specific humoral and cellular immune responses in mice. In conclusion, we evaluated the potential of this novel bacterial vesicle as a vaccine delivery system and provided a new idea for the development of SARS-CoV-2 vaccines.